SOMERSET, NJ — (BUSINESS WIRE) — February 15, 2022 — Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced that on Friday, February 11, 2022, the company was informed by the U.S Food and Drug Administration (FDA) via email communication that its Phase 1 clinical […]
SOMERSET, N.J.— (BUSINESS WIRE) —February 11, 2022— Legend Biotech Corporation(NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, has achieved two milestones under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel (cilta-cel), resulting in aggregate payments to Legend Biotech of $50 million. Cilta-cel is a B-cell maturation antigen […]
SOMERSET, N.J.— (BUSINESS WIRE) —January 4, 2022— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, will virtually participate in the 40th Annual J.P. Morgan Healthcare Conference. Ying Huang, PhD, CEO and CFO of Legend Biotech, will deliver the company presentation on Tuesday, January 11, 2022 at […]
Legend to receive an upfront payment of $350 million, as well as additional development, production performance, regulatory and sales milestone payments Legend and Janssen to co-develop and co-promote CAR-T cell therapy for multiple myeloma Profits and costs to be shared 50/50 worldwide, exclusive Greater China where 70 percent to Legend and 30 percent to Janssen […]
SOMERSET, N.J.— August 5, 2022— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today in conjunction with an announcement to be issued by Legend Biotech’s majority shareholder, GenScript Biotech Corporation, pursuant to the rules of The Stock Exchange of Hong Kong Limited, […]
There is no guarantee that the agents discussed will receive health authority approval or become commercially available in any country for the uses being investigated.
COMPLIANCE PROGRAM DECLARATION Legend Biotech USA Inc. (“Legend”) is in compliance with its Comprehensive Compliance Program (“CCP”) and California Health & Safety Code §§ 119400-119402. Our Comprehensive Compliance program, which is further described below, contains the elements of an effective compliance program identified in the “Compliance Program Guidance for Pharmaceutical Manufacturers” published by the Office […]
The links provided below redirect to third-party websites that may require a subscription to access publications.
You are going to a website that Legend Biotech does not operate and to which Legend Biotech's privacy policy does not apply. Legend Biotech is not responsible for the content, format, maintenance or policies of the website you are about to visit and does not endorse or monitor any content on such website.